Autopsy report · NCT00942422

Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

“Low accrual and early termination”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 2 years 4 months before it stopped.
• 8 participants enrolled.
• Results were posted on the registry 3 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Barbara Ann Karmanos Cancer Institute

Sponsor type

University, hospital or other

Conditions

Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition

Interventions

defined green tea catechin extract; gene expression analysis; protein analysis; laboratory biomarker analysis

Participants

8

Sites

1

Countries

United States

Trials that died the same way

• A Phase I/II Dose Escalation Study Using Extracranial Stereotactic Radiosurgery to Control Pain
  “Terminated due to low accrual” (74% match in meaning)
• Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
  “Terminated prematurely due to low accrual.” (72% match in meaning)
• Pemetrexed Plus Gemcitabine in Renal Cell Cancer
  “Closed early for poor accrual.” (70% match in meaning)
• Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
  “Closed early due to low accrual.” (68% match in meaning)
• Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
  “Terminated due to inadequate rate of accrual.” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.